IntegraGen SA (ENXTPA: ALINT)
Health Care · Biotechnology · FR
€0.18
-9.62% today · -38.9% 1Y
IntegraGen SA (ENXTPA: ALINT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.37M and employs 37 people.
Over the last twelve months the share price has lost 38.9%, trading between 0.12 and 0.36.
Tweenvest scores IntegraGen SA across four factors: quality 58/100, value 49/100, growth 0/100. Its strongest factor is quality.
ALINT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.37M
- Revenue (TTM)
- $5.90M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.34
- 52-week high
- €0.36
- 52-week low
- €0.12
- Avg volume (3M)
- —
- Shares outstanding
- 6.59M
- Employees
- 37
- Next earnings
- —
About IntegraGen SA
IntegraGen S.A. provides advanced human genome analysis services to academic researchers and life science businesses across France. Their comprehensive genomic offerings include transcriptomics, epigenomics, DNA sequencing, next-generation sequencing (NGS) specifically for cancer research, and SNP genotyping. The company also delivers clinical research solutions, such as clinical-grade sequencing and pharmacogenomic studies, in addition to supporting fundamental human genetic investigations. For agricultural applications, IntegraGen offers agrigenomic services covering crop and livestock genotyping, as well as high-throughput sequencing for these domains. Their microbial genomics division conducts whole-genome microbial sequencing and transcriptomics. IntegraGen further develops a suite of sophisticated bioinformatics tools: MERCURY is an online platform for oncology, designed to transform raw high-throughput sequencing data into molecular reports for translational and clinical research. SIRIUS, a cloud-based software, empowers researchers to analyze whole genome, whole exome, and gene panel sequencing information. Galileo is another cloud application that enables dynamic exploration of RNA-Seq expression data. Finally, GeCo, their genomic consulting service, provides researchers access to expert biostatisticians and bioanalysts. Founded in 2000 and headquartered in Évry, France, IntegraGen S.A. is a subsidiary of OncoDNA SA.
- ISIN
- FR0010908723
- Founded
- 2000
- Listed since
- Jun 18, 2010
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.